NASHVILLE, Tenn. / Sep 03, 2024 / Business Wire / Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following three investor conferences in September in New York:
H.C. Wainwright 26th Annual Global Investment Conference (Lotte New York Palace Hotel)
September 9-11, 2024
Company will present at 8:00 a.m. ET on September 10, 2024
Lake Street 8th Annual Best Ideas Growth Conference – Big 8 (The Yale Club)
September 12, 2024
1x1 Meetings Only
Cantor 2024 Global Healthcare Conference (InterContinental New York Barclay Hotel)
September 17-19, 2024
Company will host a Fireside Chat at 2:30 p.m. ET on September 18, 2024
The Company will conduct one-on-one meetings at each conference. Investors interested in meeting with management during conferences should contact their representative at each firm to request a meeting. To listen to the audio webcast of either the H.C. Wainwright or Cantor conferences, please visit the Company’s website. The Lake Street conference will not be webcast.
About Harrow
Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit harrow.com.
| Last Trade: | US$40.20 |
| Daily Change: | -1.70 -4.06 |
| Daily Volume: | 1,458,108 |
| Market Cap: | US$1.490B |
October 06, 2025 September 26, 2025 September 08, 2025 August 11, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
